home / stock / bold / bold news

BOLD News and Press, Audentes Therapeutics Inc. From 10/05/18

Stock Information
Company Name: Audentes Therapeutics Inc.
Stock Symbol: BOLD
Market: NASDAQ
Website: boundlessbio.com
Menu
BOLD BOLD Quote BOLD Short BOLD News BOLD Articles BOLD Message Board
Get BOLD Alerts

News, Short Squeeze, Breakout and More Instantly...
BOLD - Audentes Therapeutics to Provide Update on New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, from the 23rd International Annual Congress of the World Muscle Society

SAN FRANCISCO , Oct. 5, 2018 /PRNewswire/ -- Conference call and webcast Friday, October 5, 2018 at 8:30 am ET Webcast may be accessed via the Investor and Media page of the Audentes website Call may be accessed by dialing (833) 659-8620 (U.S.) or (409) 767-9247 (internationa...
BOLD - Audentes Therapeutics Presents New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, at 23rd International Annual Congress of the World Muscle Society

SAN FRANCISCO , Oct. 5, 2018 /PRNewswire/ -- Conference call and webcast Friday, October 5, 2018 at 8:30 am ET Webcast may be accessed via the Investor and Media page of the Audentes website Call may be accessed by dialing (833) 659-8620 (U.S.) or (409) 767-9247 (internation...

BOLD - Audentes Therapeutics Announces Co-Founder and Chief Executive Officer Matthew R. Patterson Appointed Chairman of the Alliance for Regenerative Medicine

SAN FRANCISCO , Oct. 3, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Co-F...

BOLD - LogicBio Therapeutics Starts U.S. IPO Process

Quick Take LogicBio Therapeutics ( LOGC ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing treatments for rare genetic diseases associated with the liver. LOGC is an extremely early stage biopharma; ...
BOLD - Audentes Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO , Sept. 26, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will...

Previous 10 Next 10